Modern strategies for the treatment of patients with autosomal dominant polycystic kidney disease

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

According to who data for 2019, kidney disease ranks 10th in the structure of the leading causes of death in the world with a total number of deaths of 1.3 million people. Based on large cohort studies, the global prevalence of chronic kidney disease (ckd) in the general population, averaged 13.4%. Autosomal dominant polycystic kidney disease (ADPKD) deserves special attention; it is characterized by the formation of cysts, a progressive increase in the volume of the kidneys with destruction of the parenchyma, a decrease in the glomerular filtration rate, and the occurrence of various complications. recently, new targeted therapeutic drugs have appeared, their action is based on the pathogenetic mechanisms of adpkd progression. The article presents a literature review of various methods in the treatment (conservative and surgical) of adpkd

Full Text

Restricted Access

About the authors

Ruslan N. Trushkin

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: uro52@mail.ru
Dr.Sci. (Med.), Head of the Department of Urology Moscow, Russia

Pavel E. Medvedev

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: pah95@mail.ru
Urologist, Urology Department Moscow, Russia

Teymur K. Isaev

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: dr.isaev@mail.ru
Cand. Sci. (Med.), Urologist, Urology Department Moscow, Russia

Tamara M. Klementieva

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: tamara-klementeva@mail.ru
Nephrologist Moscow, Russia

Nikolay V. Morozov

City Clinical Hospital № 52 of the Moscow Healthcare Department

Email: nikmorozov@rambler.ru
Urologist, Urology Department Moscow, Russia

Konstantin V. Ivanov

Moscow Multidisciplinary Clinical Center "Kommunarka" of the Moscow Healthcare Department

Urologist, Urology Department Moscow, Russia

References

  1. Bikbov B., Purcell C.A., Levey Global A.S., regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet. 2020;395(10225):709-33. doi: 10.1016/S0140-6736(20)30045-3. [Epub 2020 Feb 13].
  2. Kerr M., Bray B., Medcalf J. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol. Dial. Transplant. 2012;27(Suppl. 3): iii73-80. doi: 10.1093/ndt/gfs269. [Epub 2012 Aug 5].
  3. Мыльников М. «VADEMECUM»., разд. Мединдустрия. («Нефро-Лига» предложила Правительству РФ проиндексировать тарифы на диализ на 40-70%). 24.03.2022. https://vademec.ru/news/2022/03/24/nefro-liga-predlozhila-pravitelstvu-rf-proindeksirovat-tarify-na-dializ-na-40-70. @@Mylnikov M. "VADEMECUM", sec. Medical industry. (Nefro-Liga proposed to the Government of the Russian Federation to index tariffs for dialysis by 40-70%). 03/24/2022.
  4. U.S. Renal Data System: USRDS 2014 Annual Data Report, 2014.
  5. Grantham J.J., Torres V.E., Chapman A.B., et al. CRISP Investigators. Volume progression in polycystic kidney disease. N. Engl. J. Med. 2006; 354(20):2122-30. Doi.org/10.1056/NEJMoa054341 PMID: 16707749.
  6. Echevers Y.M., Toapanta N., Perez N.N. Survival of patients >70 years with advanced chronic kidney disease: Dialysis vs. conservative care. Nefrologia: publicacion oficial de la Sociedad Esp. Nefrol 2016;36(3). doi: 10.1016/j.nefro.2015.11.006.
  7. Helal I. Autosomal dominant polycystic kidney disease: new insights into treatment. Saudi J. Kidney Dis. Transpl. 2013;24(2):230-34. Doi. org/10.4103/1319-2442.109561 PMID: 23538343.
  8. Binsaleh S., et. al.Comparison of laparoscopic and open nephrectomy for adult polycystic kidney disease: operative challenges and technique. Canad. J. Urol. 2006;6(13):3340-45.
  9. Rim H., Jung G.S., Jung Y.S. Transcatheter arterial embolization using ethanol in a dialysis patient for contracting enlarged polycystic kidneys. Korean J. Radiol. 2010;11:574-78. doi: 10.3348/kjr.2010.11.5.574.
  10. ВОЗ: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death 09.12.2020. WHO https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death 09.12.2020.
  11. Хроническая болезнь почек (ХБП). Клинические рекомендации Минздрава России. 2021. (Электронный ресурс.) URL: https://www.rusnephrology.org/wp-content/uploads/2020/12/CKD_Jinal.pdf (дата обращения: 07.04.2022). @@Chronic kidney disease (CKD). Clinical recommendations of the Ministry of Health of the Russian Federation. 2021. (Electronic resource.) URL: https://www.rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf (access date: 07.04.2022) (in Russ.)
  12. Андрусев А.М., Томилина Н.А., Перегудова Н.Г., Шинкарев М.Б. Заместительная почечная терапия хронической болезни почек 5-й стадии в Российской Федерации 2015-2019 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Нефрология и диализ. 2021;23(3):255-329. doi: 10.28996/2618-9801-2021-3-255-329. @@Andrusev A.M., Tomilina N.A., Peregudova N.G., Shinkarev M.B. Kidney replacement therapy for end Stage Kidney Disease in Russian Federation, 2015-2019.Russian National Kidney Replacement Therapy Registry Report of Russian Public Organization of Nephrologists “Russian Dialysis Society”. Nephrol. Dial. 2021;23(3):255-329. doi: 10.28996/2618-9801-2021-3-255-329.
  13. Чугунова О.Л., Черкасова С.В., Туманова Е.Л. Поликистозная болезнь почек у новорожденных и детей раннего возраста: проблемы диагностики, ведения и лечения. Педиатрия. 2015;94(3):88-94. @@Chugunova O.L., Cherkasova S.V, Tumanova E.L. Polycystic kidney disease in newborns and young children: problems of diagnosis, management and treatment. Pediatr. 2015;94(3):88-94.
  14. Balat A. Tear drops of kidney: a historical overview of Polycystic Kidney Disease. J. Ital. Nefrol. 2016;33(Suppl. 66):33.S66.21. PMID: 26913889.
  15. Steiner P. Ueber grosscystische Degeneration der Nieren und der Leber. Deutsche Med. Wocheschr. 1899;25:677-78.
  16. Reed B., McFann K, Kimberling W.J., et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am. J. Kidney Dis.: Official J. National Kidney Foundat. 2008;52(6):1042-50. https://doi.org/10.1053/j.ajkd.2008.05.015
  17. Porath B, Gainullin V.G., Cornec-Le Gall E., et al. Mutations in GANAB, encoding the glucosidase II alpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am. J. Human. Genet. 2016;98(6):1193-207. doi: 10.1016/j.ajhg.2016.05.004.
  18. Ars E., Bernis C., Fraga G. Spanish guidelinesfor the management of autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2014; 29(Suppl. 4):iv95-105. doi: 10.1093/ndt/gfu186.
  19. Руденко Т.Е., Бобкова И.Н., Ставровская Е.В. Современные подходы к консервативной терапии поликистозной болезни почек. Тер. архив. 2019;91(6):116-23. doi: 10.26442/00403660.2019.06.000299. @@Rudenko T.E., Bobkova I.N., Stavrovskaya E.V. Modern approaches to conservative therapy of polycystic kidney disease. Ther. Arch. 2019;91(6):116-23.
  20. Reiterova J.; Tesar V. Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.Int. J. Mol. Sci. 2022;23:3317. https://doi.org/10.3390/ijms23063317
  21. Волынец Л. И., Нарезкин Д. В., Толкачев А. Н. Поликистоз почек: современное состояние проблемы. Вестник Смоленской государственной медицинской академии. Клин. медицина. УДК: 616.61-006.31. @@Volynets L.I., Narezkin D.V., Tolkachev A.N. Polycystic kidney: modern aspects of the problem. Bull. Smolensk State Med. Acad. Clin. Med. UDC: 616.61-006.31].
  22. Horie S., Mochizuki T., Muto S., et al. Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin. Exp. Nephrol. 2016;20(4):493-509. https://doi.org/10.1007/s10157-015-1219-7
  23. Grantham J.J., Chapman A.B., Torres V.E: Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin. J. Am. Soc. Nephrol. 2006;1:148-57.
  24. Chapman A.B., Bost J.E., Torres V.E., et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol 2012;7:479-86.
  25. Hayne Cho Park, Yeji Hong, Jeong-Heum Yeon, et al. Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study. Kidney Res. Clin. Pract. 2022;41(4):432-41. Published online: March 3, 2022. Doi: https://doi.org/10.23876/j.krcp.21.261.
  26. Rosenberg S., Virmani S., Klarman Sh., et al. Mayo Imaging Classification May Be Useful in Determining the Need for Nephrectomy in ADPKD. Kidney360 February. 2021;2(2):325-30. Doi: https://doi.org/10.34067/KID.0003902020.
  27. Irazabal M.V., Rangel L.J. Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials. JASN. 2015;26(1):160-72. Doi: https://doi.org/10.1681/ASN.2013101138.
  28. Tangri N., Hougen I., Alam A. Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Can. J. Kidney Health Dis. 2017;4:2054358117693355. doi: 10.1177/2054358117693355. eCollection 2017.
  29. Jones B.E., Mkhaimer Y.G., Rangel L.J. Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease. Kidney 360. 2022;3:465-76. Doi: https://doi.org/10.34067/KID.0004292021.
  30. Torres V.E., Abebe K., Chapman, et al. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. N. Engl. J. Med. 2014;371:2267-76.
  31. Супрунович К.С. Аутосомно-доминантная поликистозная болезнь почек: [Электронныйресурс]. Генокарта Генетическая энциклопедия. 2022. URL: https://www.genokarta.ru/disease/Autosomnodominantnaya_polikistoznaya_bolezn_pochek @@Suprunovich K.S. Autosomal dominant polycystic kidney disease: [Electronic resource]. Genocarda Genetic Encyclopedia. 2022. URL: http://www.genokarta.ru/disease/Autosomnodominantnaya_polikistoznaya_bolezn_pochek
  32. Woodhead J.L., Pellegrini L., Shoda L.K.M., Howell B.A.Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease Using Quantitative Systems Toxicology Modeling. Pharm. Res. 2020;37(2):24. doi: 10.1007/s11095-019-2726-0.
  33. Meijer E., Drenth J.P., dAgnolo, et al. Rationale and design of the DIPAK 1 study: A randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 2014;63(3):446-55. doi: 10.1053/j.ajkd.2013.10.011. [Epub 2013 Dec 15].
  34. Serra A.L., Poster D., Kistler A.D., et al. Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease. N. Engl. J. Med. 2010;363(9):820-9. doi: 10.1056/NEJMoa0907419. [Epub 2010 Jun 26].
  35. The National Library of Medicine (NLM). Clinical Trials.gov. https://clinicaltrials.gov.
  36. Perrone R.D., Abebe K.Z., Watnick T.J., et al. Primary results of the randomized trial of metformin administration in polycystic kideny disease (TAME PKD). Kidney Int. 2021;100(3):684-96. doi: 10.1016/j.kint.2021.06.013. [Epub 2021 Jun 27].
  37. Chediak A.E., Degheili J.A., Khauli R.B. Genitourinary Interventions in Autosomal Dominant Polycystic Kidney Disease: Clinical Recommendations for Urologic and Transplant Surgeons. Exp. Clin. Transplant. 2021;19(2):95-103. doi: 10.6002/ect.2020.0292. [Epub 2021 Jan 26].
  38. Comelis F., Couzi L., Le Bras Y., et al. Embolization of polycystic kidneys as an alternative to nephrectomy before renal transplantation: a pilot study. Am. J. Transplant. 2010;10(10):2363- 69. http://dx.doi.org/10.1111/j.1600-6143.2010.03251.x PMID: 21143393.
  39. Sallee VI., Rafat C., Zahar J.R., et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol 2009; 4(7): 1183-89. http://dx.doi.org/10.2215/ CJN.01870309 [PMID: 19470662 PMCid:PMC2709515].
  40. Lahiri S.A., Halff G.A., Speeg K.V., Esterl R.M. In-111 WBC scan localizes infected hepatic cysts and confirms their complete resection in adult polycystic kidney disease. Clin. Nucl. Med. 1998;23(l):33-4. http://dx.doi.org/10.1097/00003072-199801000-00010 PMID: 9442963
  41. Ishikawa I., Saito Y., Asaka V.I., et al. Twenty-yearfollow-up of acquired renal cystic disease. Clin. Nephrol. 2003;59(3):153-9. http://dx.doi.org/10.5414/ CNP59153 PMID: 12653256
  42. Лубенников А.Е., Нефрэктомия у больных с терминальной стадией хронической почечной недостаточности. Дисс. док. мед. наук. М., 2021. @@Lubennikov A.E., Nephrectomy in patients with end-stage chronic renal failure: author. Diss. MD. M., 2021].
  43. Amesur P., Castronuovo J.J., Chandramouly B. Infected cyst localization with gallium SPECT imaging in polycystic kidney disease. Clin. Nucl. Med. 1988; 13(l):35- 7. http://dx.doi.org/10.1097/00003072-198801000-00010 PMID: 3258216
  44. Dang J., Knebelmann B., Charlier C. FC 010 4-Week Antibiotic Therapy Prevents Recurrent Renal Cyst Infections in Autosomal Dominant Polycystic Kidney Disease. Nephrol. Dial. Transplant. 2021;36(Suppl. 1). doi: 10.1093/ndt/gfab125.003.
  45. Suwabe T. Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues. Clin. Exp. Nephrol. 2020;24:748-61. https://doi.org/10.1007/s10157-020-01928-2
  46. Kazimirov V.G., Butrin S.V., Sapozhnikov A.D. Kidney transplantation inpatients with autosomal dominant polycystic kidney disease. Volgograd: Gosudarstvennoye uchrezhdeniye «Izdatel'», 2003. 112 p.Russian (Казимиров В.Г., Бутрин С.В., Сапожников А.Д. Трансплантация почки у больных с ауто-сомно-доминантным поликистозом почек. Волгоград: Государственное учреждение «Издатель», 2003. 112 с.).
  47. Veroux M. и др. Change in kidney volume after kidney transplantation in patients with autosomal polycystic kidney disease. PloS one. 2018;12(13):e0209332.
  48. Bennett A.H., Lazarus J.M. Bilateral nephrectomy performed on an emergency basis for life-threatening malignant hypertension. Surg. Gynecol. Obstet. 1973;137(3): 451-52. [PMID: 4721516].
  49. Martin A.D., Mekeel K.L., Castle E.P., et al. Laparoscopic bilateral native nephrectomies with simultaneous kidney transplantation. BJU.Int. 2012;110(11 Pt. C):E1003-7. 22882539]' target='_blank'>http://dx.doi.Org/10.llll/j.1464-410X.2012.11379.x.[PMID: 22882539]
  50. Kirkman M.A., van Dellen D., Mehra S., et al. Native nephrectomy for autosomal dominant polycystic kidney disease: before or after kidney transplantation? BJU.Int. 2011;108(4):590-94. http://dx.doi.Org/10.llll/j.1464-410X.2010.09938.x PMID: 21166760
  51. Argyrou C., Moris D., Vernadakis S. Tailoring the ‘perfect fit’ for renal transplant recipients with end-stage polycystic kidney disease: Indications and timing of native nephrectomy. In Vivo 31:307-312, 2017. https://doi.org/10.21873/invivo.11060
  52. Brazda E., Ofner D., Riedmann B., et al. The effect of nephrectomy on the outcome of renal transplantation in patients with polycystic kidney disease. Ann. Transplant. 1996;l(2):15-8 [PMID: 9869924].
  53. Elashry O.M., Nakada S.Y., Wolf J.S., et al. Laparoscopy for adult polycystic kidney disease: a promising alternative. Am. J. Kidney Dis. 1996;27(2): 224-33. http://dx.doi.org/10.1016/50272-6386(96)90545-4
  54. Jenkins M.A., Crane J.J., Munch L.C. Bilateral hand-assisted laparoscopic nephrectomy for autosomal dominant polycystic kidney disease using a single midline HandPort incision. J. Urol. 2002;59(l):32-6. http://dx.doi.org/10.1016/50090-4295(01)01461-3
  55. Gill I.S., Kaouk J.H., Hobart M.G., et al. Laparoscopic bilateral synchronous nephrectomy for autosomal dominant polycystic kidney disease: the initial experience. J. Urol. 2001;165(4):1093-98. http://dx.doi.org/10.1016/S0022-5347(05)66435-X
  56. Lipke M.C., Bargman V., Milgrom M., Sundaram C.P. Limitations of laparoscopy for bilateral nephrectomy for autosomal dominant polycystic kidney disease. J. Urol. 2007;177(2):627-31. http://dx.doi.org/10.1016/j.juro.2006.09.026 PMID: 17222647
  57. Whitten M.G., Van Der W.W., Belnap L. A novel approach to bilateralhand-assisted laparoscopic nephrectomy for autosomal dominant polycystic kidneydisease. Surg. Endoscop. Other Interv. Techniq. 2006;4(20):679-84.
  58. Neeff H.P., Pisarski P., Tittelbach-Helmrich D., et al. One hundred consecutive kidney transplantations with simultaneous ipsilateral nephrectomy in patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2013;28(2):466-71. 23042709' target='_blank'>http://dx.doi.org/10.1093/ndt/gfsll8PMID: 23042709
  59. Sulikowski T., Tejchman K., Zietek Z., et al. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation. Transplant. Proc. 2009;41(l):177-80. http://dx.doi.org/10.1016/j.transproceed.2008.10.034 PMID: 19249508
  60. Mendez R., Mendez R.G., Payne J.E., Berne T.V. Renal transplantation. In adult patients with end stage polycystic kidney disease. J. Urol. 1975;5(l):26-7. http://dx.doi.org/10.1016/0090-4295(75)90295-2
  61. Kramer A., Sausville J., Haririan A., et al. Simultaneous bilateral native nephrectomy and living donor renal transplantation are successful for polycystic kidney disease: the University of Maryland experience. J. Urol. 2009;181(2):724-28. 19091353]' target='_blank'>http://dx.doi.org/10.1016/j.juro.2008.10.008.[PMID: 19091353]
  62. Tyson M.D., Wisenbaugh E.S., Andrews P.E., et al. Simultaneous kidney transplantation and bilateral native nephrectomy for polycystic kidney disease. J. Urol. 2013;190(6):2170-74. http://dx.doi.org/10.1016/jjuro.2013.05.057 PMID: 23727414
  63. Tabibi A., Simforoosh N., Abadpour P., et al. Concomitant nephrectomy of massively enlarged kidneys and renal transplantation in autosomal dominant polycystic kidney disease. Transplant. Proc. 2005;37(7):2939-40. 16213267]' target='_blank'>http://dx.doi.org/10.1016/j.transproceed.2005.07.053.[PMID: 16213267]
  64. Ronsin Ch., Chaba A. , Suchanek O. Incidence, Risk Factors and Outcomes of Kidney and Liver Cyst Infection in Kidney Transplant Recipient With ADPKD. Kidney Int. Rep. 2022;7:867-75. https://doi.org/10.1016/j.ekir.2022.01.1062
  65. Oguro M., Suwabe T., Ubara Y. Repetitive Refractory Renal Cyst Infection in Autosomal Dominant Polycystic Kidney Disease for which Renal Transcatheter Arterial Embolization Was Effective in Preventing Recurrence.Intern. Med. 2021;60(20):3261-65. doi: 10.2169/internalmedicine.6974-20. [Epub 2021 Oct 15].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies